and that macrophages are the effector cells (Olivotto and Bomford, 1974; Ghaffar, Cullen and Woodruff, 1975) . This is supported by the observations that C. parvum inhibits the growth of solid, subcutaneous (s.c.) tumour in both normal and T-cell-deprived mice (thymectomized, lethally irradiated and bonemarrow-reconstituted) (Davies et al., 1966) . Furthermore, macrophages from either normal, thymectomized or nude mice, if they have been treated with C. parvum, are cytotoxic for tumour cells in vitro. In contrast, the antitumour activity of C. parvum injected directly into the primary tumour does appear to be dependent on T cells, as this effect is abrogated in T-cell-deprived mice (Scott, 1974; Woodruff and Dunbar, 1975) .
The mechanism of action of C. parvum on tumour metastases may be different from that involved in the destruction of primary tumours, for there is evidence that host immunological responses can deal more effectively with disseminated tumour foci than with a single tumour Accepted 25 May 1976 mass (Carnaud, Hoch and Trainin, 1974) . Indeed, C. parvum has a more inhibitory effect on the growth of metastases than on the primary tumour (Sadler and Castro, 1976) .
In the present study the antimetastatic action of C. parvum was investigated by observing its effects on metastases from the Lewis lung carcinoma in normal mice and mice made T-cell deficient either by thymectomy and irradiation or by treatment with antilymphocyte serum (ALS).
Age-matched syngeneic female C57/BL mice (Olac) were used. Lewis lung carcinoma, which originated spontaneously as a carcinoma of the lung of a C57/BL mouse at the Wistar Institute in 1951 (Sugiura and Stock, 1955) was implanted s.c. as a 0-1-ml homogenate in the lower flank. It is a rapidly growing epidermoid carcinoma which, when implanted s.c., metastasizes to the lung (Simpson-Herren, Sanford and Holmquist, 1974) . Cells are released from the primary tumour 6 days after implantation (James and Salsbury, 1974) . Macroscopic lung metastases were counted 21 days after tumour implantation, after staining the lungs by inflation with indian ink (Wexler, 1966) .
C. parvum (Burroughs Wellcome, CN 6134, Batch PX416, 7 mg dry wt./ml) was injected i.v. at a dose of 0-466 mg in 0*2 ml normal saline. Control mice received the same volume of normal saline.
Adult thymectomy was by a method previously described (Castro, 1974) .
After 10 days, mice received 450 rad sublethal irradiation and 4 weeks later they were inoculated with tumour. Numbers of metastases were compared in both thymectomized/irradiated and control mice, with and without C. parvum. Statistical analysis was by Student's t test.
Mice received s.c. antilymphocyte serum (ALS) (Searle Diagnostics Limited, Batch 10-made by a standard 2-pulse inoculation schedule of thymocytes into rabbits) in a dose of 0-25 ml on Days 2, 1 and 0 before the tumour and then weekly. Control mice received normal rabbit serum -(NRS). The ALS used in this study was found to increase the mean survival time (MST) of Balb C tail skin allografts on C57/BL recipient mice from 13 to 19 days. Metastases were compared in both ALS-treated and control mice with and without C. parvum.
For cytoxic tests a cell suspension of the Lewis tumour was made, using the technique described by Courtenay (1976) . Finely chopped tumour was rinsed twice in PBS (Dulbecco A) and trypsinized in 0.25% trypsin (Bactotrypsin Difco diluted -'1) in PBS (up to 0 5 g tumour in 10 ml) at 370C for 10 min. The tumour was agitated and allowed to settle. The supernatant was then removed and trypsinization repeated, incubating for 10-20 min. The supernatant was again discarded and the tumour resuspended in Ham's F12 medium (Biocult) and incubated for 5-10 min. The tube was given 3-4 sharp shakes and the resulting cell suspension pipetted into a tube containing foetal calf serum (FCS) (Biocult) to give a 10% concentration. The cells were centrifuged at 350g for 10 min and resuspended in fresh medium containing 20% FCS and finally filtered through a stainless steel sieve. Viability was more than 90 %.
The toxicity of ALS for tumour cells wab determined using the cytotoxic assay described by Boyle, Ohanian and Borsos (1976) . The test was done using micro test tubes (Eppendorf) containing 105 Lewis tumour cells, suspended in 0-1 ml Ham's F12 medium with 20% FCS.
Prepared tubes were incubated with an equal volume of serum for 30 min at 30°C. The serum was from normal mice which had received s.c. ALS or NRS on Days -2, -1, 0 and + 7, taken at 2 h, 24 h or 4 days after the last s.c. injection, or from untreated mice. Appropriate positive and negative controls were included in the test. The tubes were centrifuged at 350g for 10 min, the supernatant discarded and the cells resuspended in 0-1 ml medium containing FOS. They were then incubated for 1 h at 37TC in the presence of 0'1 ml of a 1: 8 dilution guinea-pig complement (Wellcome) . The cells were then mixed with Trypan blue and the number of cells taking up the dye was assessed by visual counting in a haemocytometer.
The phagocytic index, K, in tumourbearing mice treated with ALS or NRS, and C. parvum was measured by clearance of colloidal carbon from the blood, using a modification of the technique described by Biozzi et al. (1954) . Mice were bled from the retro-orbital plexus at 2, 5, 10, 15 and 20 min after an i.v. injection of colloidal carbon (14.5% Pelican ink, 1% gelatin in water given at 0.01 ml/g body wt) using 0*02-ml Benjamin heparinized haematocrit tubes. The blood was lysed in 2 ml of water and the optical density D determined in a Unicam colorimeter with a 650-mm red filter. K was calculated for each mouse by the method of least squares, as a regression coefficient multiplied by-1, of the straight line relating to the logarithms of the D reading plotted against time. A combined estimate of K and standard error was determined for each group.
C. parvum greatly inhibited the number of metastases occurring in normal mice (Tables I and II) . There was an equivalent number of metastases in the thymectomized as in normal mice and this number was significantly reduced after C. parvum (Table I) . ALS-treated mice had significantly fewer metastases than those given NRS, and this number was not further decreased after C. parvum (Table II) . The cytotoxity of sera from normal mice which had received the same regime of NRS and ALS as the tumour-bearing mice (i.e., s.c. injections on Days -2, -1, 0 and + 7) was studied. Serum was taken by cardiac puncture at 2 h, 24 h and 4 days after the last injection, on Day 7. The results are shown in Table III . Sera from both NRS-and ALS-treated mice were not cytotoxic.
The phagocytic index, K, for tumourbearing mice treated with NRS or ALS, and C. parvum was determined 8 days after tumour implantation (Table IV) . C. parvum increased the K in both NRSand ALS-treated mice. There was no significant differences between mice receiving NRS or ALS. The antimetastatic action of C. parvum was investigated using the Lewis lung carcinoma, a tumour which when grown s.c. metastasizes naturally to the lungs (Simpson-Herren et al., 1974) . Reported experiments using primary tumour have indicated that T cell involvement in the anti-tumour response to C. parvum depends upon the route of injection of this vaccine (Woodruff et al., 1973; Scott, 1974; Woodruff and Dunbar, 1975) . The importance of T cells in the response of the host against metastases after C. parvum injection was investigated by depleting mice of these cells by thymectomy and irradiation, or by treatment with ALS.
When compared with controls there was no significant change in the numbers of metastases in thymectomized irradiated mice. In such mice the antimetastatic effects of C. parvum were unchanged. These findings may be comparable with the results obtained by Woodruff and Dunbar (1975) and Scott (1974) on solid tumours in T-cell-deficient mice. However, the depletion of T cells in our experiments was less than in their thymectomized, lethally irradiated and reconstituted mice. There was a significant reduction in the number of metastases in ALS-treated mice when compared with those given NRS. This inhibition could be explained if ALS was directly cytotoxic for tumour cells. However, sera taken from ALStreated normal mice at a time in the schedule of ALS injection when malignant cells would be in the circulation of tumourbearing mice (James and Salsbury, 1974) , was found not to be cytotoxic for Lewis tumour cells.
Another explanation for the reduction in number of metastases after ALS treatment could be that a specific subpopulation of T cells is required for the optimal growth of these metastases. Indeed, tumour-enhancing T lymphocytes have been reported in the Lewis lung system (Treves et al., 1974) ; Umiel and Trainin, 1974) . The observation that thymectomy and irradiation did not inhibit metastases, whereas ALS caused their reduction, might be explained if these 2 procedures affect different subpopulations of lymphocytes. Indeed, ALS has been shown to destroy circulating T lymphocytes, leaving unharmed shortlived, rapidly turned-over T cells resident within the spleen and lymph nodes (Lance, Medawar and Taub, 1973; Araneo, Marrack and Kappler, 1975) . Both thymectomized, irradiated and reconstituted (Woodruff et al., 1973; Gillette and Fox, 1975) and nude mice (Raff, 1973) possess some T cells, and thymectomy alone has been reported to deplete only short-lived T cells (Kappler et al., 1974) . Such observations support the contention that ALS destroys tumour-enhancing lymphocytes.
C. parvum had no antimetastatic activity in mice that had received ALS. Recent work by Christie and Bomford (1975) has shown that peritoneal macrophages from untreated mice cannot be activated in vitro by C. parvum alone but only when C. parvum is added with 0-sensitive immune spleen cells. This suggests that the action of C. parvum on metastases is dependent upon a specific population of long-lived circulating T cells.
The abrogation of the antimetastatic effects of C. parvum by ALS might also be explained if this serum had an effect on macrophages. ALS has been shown to affect macrophage activity in vitro (Hughes et al., 1971; Jakobsen, 1973) but when we determined the activity in vivo (by clearance of carbon) it did not differ significantly in mice treated with ALS from controls given NRS.
There is considerable evidence that macrophages are involved in the antitumour action of C. parvum (Ghaffar et al., 1975; Christie and Bomford, 1975) . Therefore, we postulate that the mechanism of inhibition of metastases after i.v. administration of C. parvum involves the activation of macrophages in vivo through a specific subpopulation of T cells (or their products) present in thymectomized and irradiated but not ALS-treated mice. Further studies are being undertaken to determine the particular population of T cells involved.
